Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Expenses: 2016-2025

Historic Operating Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $330.8 million.

  • Ultragenyx Pharmaceutical's Operating Expenses rose 21.86% to $330.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 10.97%. This contributed to the annual value of $1.1 billion for FY2024, which is 9.24% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Operating Expenses is $330.8 million, which was up 20.57% from $274.4 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Operating Expenses high stood at $330.8 million for Q3 2025, and its period low was $169.8 million during Q2 2021.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Operating Expenses value was $271.5 million (recorded in 2024), while the average stood at $271.6 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Operating Expenses spiked by 84.15% in 2022 and then declined by 23.00% in 2023.
  • Ultragenyx Pharmaceutical's Operating Expenses (Quarterly) stood at $186.0 million in 2021, then spiked by 33.89% to $249.0 million in 2022, then climbed by 0.19% to $249.4 million in 2023, then rose by 15.12% to $287.2 million in 2024, then grew by 21.86% to $330.8 million in 2025.
  • Its Operating Expenses was $330.8 million in Q3 2025, compared to $274.4 million in Q2 2025 and $282.2 million in Q1 2025.